Jefferies initiates MiniMed Group stock coverage with hold rating
Jefferies initiated coverage on MiniMed Group (NASDAQ:MMED) with a Hold rating and a $22.00 price target, citing improved performance and competitive position. The stock trades at $19.71, with a Fair Value of $22.63 according to InvestingPro. The company reported Q1 revenue of $843 million, up 17% YoY, exceeding expectations. Analysts predict profitability this year, with varied price target updates from other firms.
How this was made
The 30-second read
Why it matters
The initiation of coverage provides fresh guidance and may set a new valuation baseline for the stock.
Market read
The article introduces new analyst coverage and price target for MMED, offering traders a fresh data point for valuation.
What to watch
Potential upside from the pending Medtronic split‑off and future product launches may not be fully priced in.
Background
Jefferies' new coverage follows MiniMed's Q1 earnings beat and multiple analyst upgrades, highlighting its improving competitive position.
Ticker impact
Jefferies initiated coverage on MiniMed Group with a Hold rating and a $22 price target, citing Q1 revenue beat and analyst upgrades.
likely pressure as the market prices in limited upside from the hold rating and $22 target
New coverage provides fresh guidance but the hold rating and modest target suggest limited near-term catalyst.
Market effects
The coverage may influence other CGM and medtech stocks as analysts reassess valuation benchmarks.
Primarily U.S. market impact; limited effect on broader regional indices.
Low global relevance beyond the medtech sector.
Counterpoint
Despite the hold rating, the recent revenue beat and analyst upgrades could support a short-term rally.
Key entities
- CompanyMiniMed Group
Medical device company focusing on continuous glucose monitors.
- Research FirmJefferies
Investment bank that initiated coverage with a Hold rating.
